Erytech Could Launch Several New Studies Following Pancreatic Cancer PhII Success

 
• By Lucie Ellis-Taitt

Erytech's lead therapy has shown strong anti-cancer activity in pancreatic cancer, on top of the hematological indications it is already targeting in late-stage trials, spelling good news for the French firm to pursue more studies in other oncology indications such as ovarian cancer.

Cancer cells
Erytech's positive pancreatic cancer data could push the company towards other solid tumor indications

More from Clinical Trials

More from R&D